TMCnet News

Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
[November 13, 2014]

Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/9c49lp/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.

The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018

A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS (News - Alert)), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobi, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs.



The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error.

The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market.


According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease.

Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death.

Key Vendors

  • Abbott Laboratories
  • Alere
  • Ortho Clinical Diagnostics
  • Roche Diagnostics

For more information visit http://www.researchandmarkets.com/research/9c49lp/global_cardiac


[ Back To TMCnet.com's Homepage ]